10-Q: Delcath Systems Reports Strong Q3 Growth, Positive Trial Data

Delcath Systems, Inc. announced significant revenue growth and a positive shift to profitability for the nine months ended September 30, 2025, driven by HEPZATO and CHEMOSAT sales and promising clinical trial results.

Summary

• Product revenue for the nine months ended September 30, 2025, increased by 191.8% to $64.5 million, up from $22.1 million in the same period of 2024.
• Gross profit for the nine months ended September 30, 2025, rose by 208.8% to $55.7 million, compared to $18.0 million in the prior year.
• Operating income for the nine months ended September 30, 2025, was $2.8 million, a significant improvement from an operating loss of $15.4 million in the same period of 2024.
• Net income for the nine months ended September 30, 2025, was $4.6 million, a substantial turnaround from a net loss of $23.0 million in the prior year.
• Basic income per common share for the nine months ended September 30, 2025, was $0.13, compared to a loss of $0.84 in the same period of 2024.
• Cash and cash equivalents totaled $41.8 million and short-term investments were $47.1 million as of September 30, 2025, providing $88.9 million in total liquidity.
• The CHOPIN Phase 2 clinical trial met its primary endpoint, showing a one-year progression-free survival rate of 54.7% in the combination group versus 15.8% in the PHP group.
• Median Overall Survival (OS) in the CHOPIN trial was 23.1 months for the combination group versus 19.6 months for the PHP group (HR = 0.39; p = 0.006).
• Median Progression-Free Survival (PFS) in the CHOPIN trial was 12.8 months for the combination group versus 8.3 months for the PHP group (HR = 0.34; p<0.001).
• Overall Response Rate (ORR) in the CHOPIN trial was 76.3% for the combination group versus 39.5% for the PHP group (p<0.001).
• Patient enrollment began in Q3 2025 for the Phase 2 clinical trial evaluating HEPZATO in combination with standard of care for liver-dominant metastatic colorectal cancer (mCRC).
• The IND application for a Phase 2 clinical trial of HEPZATO in liver-dominant HER2-negative metastatic breast cancer (mBC) was cleared by the FDA on April 28, 2025.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant revenue growth and a shift to profitability, coupled with positive clinical trial results for its lead products and expansion into new indications. This indicates strong operational execution and promising future growth potential. While R&D and SG&A expenses are increasing, this is tied to strategic growth initiatives. Regulatory risks are noted but are common for the industry.

Positives

• Significant revenue growth for both HEPZATO and CHEMOSAT, with total product revenue increasing by 191.8% to $64.5 million for the nine months ended September 30, 2025.
• Achieved positive operating income of $2.8 million and net income of $4.6 million for the nine months ended September 30, 2025, a substantial turnaround from losses in the prior year.
• Strong liquidity position with $41.8 million in cash and cash equivalents and $47.1 million in short-term investments as of September 30, 2025.
• Positive results from the investigator-initiated CHOPIN Phase 2 clinical trial, demonstrating superior one-year progression-free survival, overall survival, and overall response rate for CHEMOSAT combined with immune checkpoint inhibitors.
• Expansion of clinical development pipeline with the initiation of patient enrollment for a Phase 2 trial in liver-dominant metastatic colorectal cancer (mCRC) and FDA clearance for a Phase 2 trial in liver-dominant HER2-negative metastatic breast cancer (mBC).
• CHEMOSAT received reimbursement approval for two years in the Vastra Gotaland Region in Sweden in June 2025.
• Current cash, cash equivalents, investments, and net cash provided by operating activities are believed to be sufficient to support current operations for at least 12 months.
• The One Big Beautiful Bill (OBBB) signed on July 4, 2025, resulted in a decrease in the current tax provision from $0.7 million to $0.2 million for the nine months ended September 30, 2025, due to full expensing of U.S. R&D costs.

Negatives

• Research and development expenses increased by 81.3% to $19.9 million for the nine months ended September 30, 2025, due to clinical team expansion and new trial initiations.
• Selling, general and administrative expenses increased by 46.4% to $33.0 million for the nine months ended September 30, 2025, driven by commercial expansion activities and increased personnel costs.
• Net income for the three months ended September 30, 2025, was $0.8 million, a decrease from $1.9 million in the same period of 2024, primarily due to a non-recurring gain in the prior year related to warrant liability fair value adjustment.
• Investing activities used $26.0 million in cash for the nine months ended September 30, 2025, primarily for the purchase of investments.

Risks

• Failure to comply with reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs could lead to additional reimbursement requirements, penalties, sanctions, and fines.
• Pricing and rebate calculations are complex and subject to interpretation by governmental agencies and courts, which can change and evolve over time, potentially leading to increased costs or liabilities.
• Changes in healthcare law and implementing regulations, including government restrictions on pricing and reimbursement (e.g., Inflation Reduction Act of 2022, One Big Beautiful Bill), could negatively impact business, drug approval, sales, and profits.
• The overturning of the Chevron doctrine by the U.S. Supreme Court in Loper Bright Enterprises v. Raimondo could lead to additional legal challenges to current regulations and guidance from federal agencies like the FDA.
• Uncertainty regarding future tax reform legislation, including potential changes to the One Big Beautiful Bill, could materially impact deferred tax assets and future tax expense.
• Risks common to the biopharmaceutical industry, including challenges in developing product candidates, obtaining regulatory approvals, achieving broad market adoption, and significant competition.
• Economic uncertainties such as high inflation, rising interest rates, and volatility in financial markets could increase risks and affect the ability to access additional capital on favorable terms.
• Supply chain disruptions due to geopolitical events, global health outbreaks, adverse weather, labor/raw material shortages, tariffs, or trade restrictions could cause manufacturing difficulties, delays, product shortages, increased costs, and damage to reputation.

Future Outlook

The company expects continued clinical adoption and reimbursement for CHEMOSAT in Europe and HEPZATO in the United States, supported by ongoing clinical development programs. It anticipates increased research and development expenses due to the initiation and progression of Phase 2 clinical trials for liver-dominant metastatic colorectal cancer and metastatic breast cancer. The company believes its current liquidity will be sufficient to support operations for at least the next 12 months.

Management Comments

• We have sufficient raw material and component constituent parts of the HEPZATO KIT to meet anticipated demand and we intend to manage supply chain risk through stockpiled inventory and contracting with multiple suppliers for critical components.
• Overall, the combination treatment [in CHOPIN trial] was well tolerated, with types, rates and frequencies of adverse events consistent with individual use of PHP and checkpoint inhibitors. No new safety signals were identified.
• We expect that the publication [of FOCUS Trial data] will support increased clinical adoption of and reimbursement for CHEMOSAT in Europe, and support reimbursement in various jurisdictions, including the United States.
• We believe that these and similar disease states [mCRC, mBC, neuroendocrine tumors, intrahepatic cholangiocarcinoma] are areas of unmet medical needs that represent significant market opportunities.
• We estimate that the total addressable market (TAM) for liver-dominant mCRC receiving third-line treatment is between 6,000 and 10,000 patients annually in the United States.
• We estimate that approximately 7,000 patients annually in the United States are affected by HER2-negative metastatic breast cancer with liver metastases and are candidates for third line treatment.
• We expect our research and development expenses to increase for the foreseeable future relating to the costs required to complete these Phase 2 clinical trials.
• We believe that our current cash on hand, cash equivalents, investments and net cash provided by operating activities will be sufficient to support our current operations through at least 12 months from the issuance of these consolidated financial statements.

Industry Context

The company operates in the interventional oncology space, focusing on liver-directed therapies for metastatic cancers. The positive CHOPIN trial results for combination therapy with immune checkpoint inhibitors align with a broader industry trend towards multimodal cancer treatments that integrate targeted therapies with immunotherapies to improve patient outcomes. The expansion into metastatic colorectal cancer and breast cancer addresses significant unmet medical needs in large patient populations, positioning the company to potentially capture market share in these competitive oncology segments. Regulatory changes like the Inflation Reduction Act and the One Big Beautiful Bill reflect ongoing governmental efforts to control healthcare costs and drug pricing, which could impact the pharmaceutical industry broadly.

Comparison to Industry Standards

• The CHOPIN trial's one-year progression-free survival rate of 54.7% for the combination group (CHEMOSAT + ICI) versus 15.8% for PHP alone demonstrates a significant improvement in efficacy, which is a strong indicator in oncology trials, especially for advanced metastatic disease.
• The median Overall Survival (OS) of 23.1 months for the combination group compared to 19.6 months for PHP alone, with a Hazard Ratio (HR) of 0.39 (p = 0.006), suggests a clinically meaningful survival benefit, which is a critical benchmark for new cancer therapies.
• An Overall Response Rate (ORR) of 76.3% in the combination group is exceptionally high for advanced metastatic cancers, particularly when compared to the 39.5% for PHP alone, indicating a robust tumor response.
• The FOCUS trial's ORR of 36.3% for HEPZATO in mUM was statistically significantly better than the pooled ORR estimate of 5.5% in the historical control group, establishing a strong efficacy profile against existing benchmarks for this rare disease.
• The company's expansion into liver-dominant metastatic colorectal cancer (mCRC) and HER2-negative metastatic breast cancer (mBC) targets patient populations with limited third-line treatment options, where current standard of care often yields lower response rates and shorter survival times, suggesting a high potential for unmet need.

Corporate Governance

Legal Proceedings

• The company has an estimated remaining fair value of $0.8 million as of September 30, 2025, related to the settlement of a dispute with medac GmbH.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to strong revenue growth, profitability, positive clinical trial results, and expansion into new markets. Dilution risk from potential future capital raises under the shelf registration.
• Patients: Improved treatment options for uveal melanoma patients with HEPZATO KIT. Potential for new treatment options for liver-dominant metastatic colorectal cancer and HER2-negative metastatic breast cancer patients through ongoing clinical trials.
• Employees: Increased headcount in clinical and commercial teams, leading to more employment opportunities. Stock-based compensation plans provide incentives.
• Hospitals/Treatment Centers: Continued access to HEPZATO KIT and CHEMOSAT for treating liver cancers. New reimbursement approval for CHEMOSAT in Sweden.
• Suppliers: Continued demand for raw materials and components, with a commitment to purchase $2.5 million of melphalan in 2026.

Next Steps

• Continue commercial expansion and drive demand for HEPZATO in the United States and CHEMOSAT in Europe.
• Generate additional clinical data for CHEMOSAT and HEPZATO as monotherapy or in combination with immunotherapy to support increased clinical adoption and reimbursement.
• Continue patient enrollment for the Phase 2 clinical trial evaluating HEPZATO in combination with standard of care for liver-dominant metastatic colorectal cancer (mCRC), with hPFS readout anticipated by end of 2027 and OS in 2028.
• Begin patient enrollment in the first quarter of 2026 for the Phase 2 clinical trial of HEPZATO in liver-dominant HER2-negative metastatic breast cancer (mBC), with hPFS readout anticipated by end of 2028 and OS in 2029.
• Monitor and comply with reporting and payment obligations under the Medicaid Drug Rebate Program and other governmental pricing programs.
• Evaluate the effects of ASU 2024-03 (Expense Disaggregation Disclosures) and ASU 2023-09 (Improvements to Income Tax Disclosures) on financial statements.
• Monitor the implementation and effect of tariffs and other proposed trade restrictions.
• Manage supply chain risk through stockpiled inventory and contracting with multiple suppliers for critical components.
• Purchase $2.5 million of melphalan under the Supply Agreement in 2026.

Key Dates

Recommendation

The company has demonstrated exceptional financial performance, achieving a significant turnaround from losses to profitability with nearly 200% revenue growth for the nine months ended September 30, 2025. The positive results from the CHOPIN Phase 2 trial, showing superior efficacy for combination therapy, are a major catalyst, validating the platform's potential beyond its initial indication. The expansion into large addressable markets like metastatic colorectal and breast cancer, backed by FDA clearances for Phase 2 trials, indicates a robust growth pipeline. With a strong liquidity position and positive operating cash flow, the company is well-funded for its near-term strategic initiatives. While R&D and SG&A expenses are rising, they are directly linked to commercial expansion and clinical development, which are essential for long-term value creation. The overall trajectory suggests strong upside potential for investors.

Keywords

Delcath Systems, DCTH, HEPZATO KIT, CHEMOSAT, Uveal Melanoma, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Interventional Oncology, Drug-Device Combination, Clinical Trials, FDA Approval, Orphan Drug, Financial Results, Q3 2025, Biopharmaceutical, Oncology, Medical Device, SEC Filing, Earnings, Revenue Growth, Profitability, Cash Flow, CHOPIN Trial, FOCUS Trial, Melphalan, Immune Checkpoint Inhibitors, Reimbursement, Regulatory Risk, Tax Law Changes